摘要
目的探讨氟伏沙明合并利培酮对强迫性障碍患者的疗效及安全性。方法选取2017年1月~2019年12月期间我院120例强迫性障碍患者作为研究对象。按照不同治疗方案进行分组,对照组60例强迫性障碍症患者仅马来酸氟伏沙明治疗,而观察组60例强迫性障碍症患者在对照组治疗基础上联合利培酮治疗,比较两组疗效和不良反应。结果观察组总有效率为96.67%,高于对照组85.00%(P<0.05)。两组患者治疗前Y-BOCS和HAMA评分无明显差异(P>0.05),治疗4W、8W后两组患者都改善,且观察组各项评分均明显低于对照组(P<0.05)。两组患者不良反应发生率以及TESS评分均无明显差异(P>0.05)。结论氟伏沙明联合利培酮对强迫性障碍患者具有更好的疗效,且安全性较高。
Objective To analyze the efficacy and safety of fluvoxamine combined with risperidone in the treatment of obsessive-compulsive disorder. Methods 120 patients with obsessive-compulsive disorder in our hospital from January 2017 to December 2019 were selected and divided into two groups,the control group(n=60)were treated only with fluvoxamine,while the observation group(n=60)were treated with fluvoxamine combined with risperidone. The efficacy and safety were compared between two groups. Results The total effective rate was in the observation group(96.67%)was higher than that(85.00%)in the control group(P<0.05). Before treatment,there was no difference in Y-BOCS and HAMA scores between two groups;After 4 W and 8 W of treatment,the Y-BOCS and HAMA scores in both of two group were decrease(P<0.05),and the scores of the observation group were significantly lower than those of the control group(P<0.05). There was no significant difference in adverse reaction rate and TESS score between the two groups(P>0.05). Conclusion Fluvoxamine combined with risperidone can improve the clinical efficacy in patients with obsessive-compulsive disorder with high safety.
作者
孔惠婷
肖一妙
郑珺珺
王晶
KONG Huiting;XIAO Yimiao;ZHENG Junjun(The Fifth People's Hospital of Luoyang,Luoyang 471000,China)
出处
《国际精神病学杂志》
2020年第2期319-321,共3页
Journal Of International Psychiatry
关键词
氟伏沙明
利培酮
强迫性障碍
疗效
安全性
Fluvoxamine
Risperidone
Obsessive-compulsive disorder
Efficacy
Safety
